Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Acute Lung Injury-Pipeline Review, H1 2015

Acute Lung Injury-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Acute Lung Injury-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Acute Lung Injury-Pipeline Review, H1 2015', provides an overview of the Acute Lung Injury's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Lung Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Lung Injury and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Acute Lung Injury

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Acute Lung Injury and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Acute Lung Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Acute Lung Injury pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Acute Lung Injury

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Acute Lung Injury pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Acute Lung Injury Overview 10

Therapeutics Development 11

Pipeline Products for Acute Lung Injury-Overview 11

Pipeline Products for Acute Lung Injury-Comparative Analysis 12

Acute Lung Injury-Therapeutics under Development by Companies 13

Acute Lung Injury-Therapeutics under Investigation by Universities/Institutes 16

Acute Lung Injury-Pipeline Products Glance 18

Clinical Stage Products 18

Early Stage Products 19

Acute Lung Injury-Products under Development by Companies 20

Acute Lung Injury-Products under Investigation by Universities/Institutes 22

Acute Lung Injury-Companies Involved in Therapeutics Development 23

Altor BioScience Corporation 23

Apeptico Forschung und Entwicklung GmbH 24

BioMarck Pharmaceuticals, Ltd. 25

Carolus Therapeutics, Inc. 26

CompleGen, Inc. 27

FirstString Research, Inc. 28

GlaxoSmithKline Plc 29

Histocell S.L. 30

Navigen Pharmaceuticals, Inc. 31

Noxxon Pharma AG 32

S-Evans Biosciences, Inc. 33

Silence Therapeutics Plc 34

Stemedica Cell Technologies, Inc. 35

Therametrics holding AG 36

Xiber Science GmbH 37

Acute Lung Injury-Therapeutics Assessment 38

Assessment by Monotherapy Products 38

Assessment by Target 39

Assessment by Mechanism of Action 41

Assessment by Route of Administration 43

Assessment by Molecule Type 45

Drug Profiles 47

ALT-836-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

AP-301-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Atu-111-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

Atu-112-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

BC-1215-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

BIO-10901-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

CGX-1037-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

CT-2009-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

DasKloster-0141-01-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

DasKloster-100004-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

Drugs to Antagonize IGF-1 Receptor for Acute Lung Injury and Pulmonary Fibrosis-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

Drugs to Inhibit Adenosine A1 Receptor for Lung Injury and Lung Inflammation-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

GSK-2586881-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

GSK-2862277-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

HC-016-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

LTI-02-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

Mesenchymal Stem Cells-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

MG-53-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

Monoclonal Antibody 1 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

Monoclonal Antibody 2 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

Monoclonal Antibody to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

NOXD-19-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

P- BEFizumab-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

Peptide to Activate PAI-1 for Acute Lung Injury-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

Recombinant Protein for Acute Lung Injury, Sepsis and Chronic Inflammation-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

S-1229-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

Small Molecules for Inflammatory Diseases and Sepsis-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

Small Molecules to Inhibit Arf6 for Multiple Diseases-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

Stem Cell Therapy for Acute Lung Injury-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

Stem Cell Therapy for Inflammatory Lung Diseases-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

Stem Cell Therapy for Metabolic, Gastrointestinal and Respiratory Disorders-Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

Stromal Cell Therapy for Acute Lung Injury-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

Synthetic Peptide for Acute Lung Injury and Acute Respiratory Distress Syndrome-Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

Synthetic Peptides for Respiratory Distress Syndrome and Acute Lung Injury-Drug Profile 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

TXA-302-Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

Xib-1301-Drug Profile 91

Product Description 91

Mechanism of Action 91

R&D Progress 91

Acute Lung Injury-Recent Pipeline Updates 92

Acute Lung Injury-Dormant Projects 98

Acute Lung Injury-Discontinued Products 100

Acute Lung Injury-Product Development Milestones 101

Featured News & Press Releases 101

Aug 05, 2014: Silence Therapeutics Announces Publication of pre-clinical study data on use of Atu111 RNAi in sepsis 101

Sep 10, 2012: Silence Therapeutics' Proof Of Concept Study In Preclinical Model Shows Survival Benefit With Atu111 In Combination With Antibiotics 101

Jan 20, 2012: Carolus Therapeutics Reports Publication Of Preclinical Data For CT-2009 Supporting Development In Acute Lung Injury 102

Dec 19, 2011: Apeiron Biologics Announces Initiation Of Phase IIa Study In Acute Lung Injury Patients 103

May 23, 2011: Altor BioScience Receives $3m SBIR Phase II Competing Renewal Grant From NHLBI 103

Sep 08, 2009: APEPTICO Presents Lead Product AP301 At Annual Congress Of European Respiratory Society In Vienna, Austria 104

Appendix 105

Methodology 105

Coverage 105

Secondary Research 105

Primary Research 105

Expert Panel Validation 105

Contact Us 105

Disclaimer 106

List of Tables

Number of Products under Development for Acute Lung Injury, H1 2015 11

Number of Products under Development for Acute Lung Injury-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 14

Number of Products under Development by Companies, H1 2015 (Contd..1) 15

Number of Products under Investigation by Universities/Institutes, H1 2015 17

Comparative Analysis by Clinical Stage Development, H1 2015 18

Comparative Analysis by Early Stage Development, H1 2015 19

Products under Development by Companies, H1 2015 20

Products under Development by Companies, H1 2015 (Contd..1) 21

Products under Investigation by Universities/Institutes, H1 2015 22

Acute Lung Injury-Pipeline by Altor BioScience Corporation, H1 2015 23

Acute Lung Injury-Pipeline by Apeptico Forschung und Entwicklung GmbH, H1 2015 24

Acute Lung Injury-Pipeline by BioMarck Pharmaceuticals, Ltd., H1 2015 25

Acute Lung Injury-Pipeline by Carolus Therapeutics, Inc., H1 2015 26

Acute Lung Injury-Pipeline by CompleGen, Inc., H1 2015 27

Acute Lung Injury-Pipeline by FirstString Research, Inc., H1 2015 28

Acute Lung Injury-Pipeline by GlaxoSmithKline Plc, H1 2015 29

Acute Lung Injury-Pipeline by Histocell S.L., H1 2015 30

Acute Lung Injury-Pipeline by Navigen Pharmaceuticals, Inc., H1 2015 31

Acute Lung Injury-Pipeline by Noxxon Pharma AG, H1 2015 32

Acute Lung Injury-Pipeline by S-Evans Biosciences, Inc., H1 2015 33

Acute Lung Injury-Pipeline by Silence Therapeutics Plc, H1 2015 34

Acute Lung Injury-Pipeline by Stemedica Cell Technologies, Inc., H1 2015 35

Acute Lung Injury-Pipeline by Therametrics holding AG, H1 2015 36

Acute Lung Injury-Pipeline by Xiber Science GmbH, H1 2015 37

Assessment by Monotherapy Products, H1 2015 38

Number of Products by Stage and Target, H1 2015 40

Number of Products by Stage and Mechanism of Action, H1 2015 42

Number of Products by Stage and Route of Administration, H1 2015 44

Number of Products by Stage and Molecule Type, H1 2015 46

Acute Lung Injury Therapeutics-Recent Pipeline Updates, H1 2015 92

Acute Lung Injury-Dormant Projects, H1 2015 98

Acute Lung Injury-Dormant Projects (Contd..1), H1 2015 99

Acute Lung Injury-Discontinued Products, H1 2015 100

List of Figures

Number of Products under Development for Acute Lung Injury, H1 2015 11

Number of Products under Development for Acute Lung Injury-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 13

Number of Products under Investigation by Universities/Institutes, H1 2015 16

Comparative Analysis by Clinical Stage Development, H1 2015 18

Comparative Analysis by Early Stage Products, H1 2015 19

Assessment by Monotherapy Products, H1 2015 38

Number of Products by Top 10 Targets, H1 2015 39

Number of Products by Stage and Top 10 Targets, H1 2015 39

Number of Products by Top 10 Mechanism of Actions, H1 2015 41

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 41

Number of Products by Top 10 Routes of Administration, H1 2015 43

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 43

Number of Products by Top 10 Molecule Types, H1 2015 45

Number of Products by Stage and Top 10 Molecule Types, H1 2015 45

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Altor BioScience Corporation

Apeptico Forschung und Entwicklung GmbH

BioMarck Pharmaceuticals, Ltd.

Carolus Therapeutics, Inc.

CompleGen, Inc.

FirstString Research, Inc.

GlaxoSmithKline Plc

Histocell S.L.

Navigen Pharmaceuticals, Inc.

Noxxon Pharma AG

S-Evans Biosciences, Inc.

Silence Therapeutics Plc

Stemedica Cell Technologies, Inc.

Therametrics holding AG

Xiber Science GmbH

Acute Lung Injury Therapeutic Products under Development, Key Players in Acute Lung Injury Therapeutics, Acute Lung Injury Pipeline Overview, Acute Lung Injury Pipeline, Acute Lung Injury Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com